New hope for rare sugar disorder: experimental drug aims to slash dangerous lows
NCT ID NCT06208215
First seen Jan 09, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study tests an investigational drug called RZ358 in 56 people aged 3 months to 45 years with congenital hyperinsulinism, a rare condition causing dangerously low blood sugar. Participants receive RZ358 or a placebo added to their usual treatments for 24 weeks, followed by an open-label period where everyone can get RZ358. The goal is to see if RZ358 reduces hypoglycemia events and improves safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL HYPERINSULINISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cook Children's Medical Center
Fort Worth, Texas, 76104, United States
-
Rezolute Investigative Site, Al Rayyan, Qatar
Al Rayyan, Qatar
-
Rezolute Investigative Site, Ankara, Turkey
Ankara, 06800, Turkey (Türkiye)
-
Rezolute Investigative Site, Athens, Greece
Athens, 115 27, Greece
-
Rezolute Investigative Site, Barcelona, Spain
Barcelona, 08035, Spain
-
Rezolute Investigative Site, Berlin, Germany
Berlin, 13353, Germany
-
Rezolute Investigative Site, Bron, France
Bron, 69677, France
-
Rezolute Investigative Site, Dusseldorf, Germany
Düsseldorf, 40225, Germany
-
Rezolute Investigative Site, Hà Nội, Vietnam
Hà Nội, 100000, Vietnam
-
Rezolute Investigative Site, London, United Kingdom
London, WC1N 3JH, United Kingdom
-
Rezolute Investigative Site, Manchester, United Kingdom
Manchester, M13 9WL, United Kingdom
-
Rezolute Investigative Site, Odense, Denmark
Odense, 5000, Denmark
-
Rezolute Investigative Site, Paris, France
Paris, 75015, France
-
Rezolute Investigative Site, Seeb, Oman
Seeb, 123, Oman
-
Rezolute Investigative Site, Sevilla, Spain
Seville, 41013, Spain
-
Rezolute Investigative Site, Tbilisi, Georgia
Tbilisi, 0159, Georgia
-
Rezolute Investigative Site, Varna, Bulgaria
Varna, 9010, Bulgaria
Conditions
Explore the condition pages connected to this study.